Neurimmune Therapeutics AG, an early stage biotechnology firm specializing in developing antibody-based therapies for neurodegenerative conditions, entered an alliance on Alzheimer's disease with Biogen Idec worth up to $380 million in up-front and milestone payments. Neurimmune also would receive royalties on eventual product sales. (BioWorld International)

Antisense Pharma GmbH raised €27 million (US$39.5 million) in a third investment round funded solely by MIG AG, which also was the only investor in its €18 million funding round two years ago. (BioWorld International)